论文部分内容阅读
目的:研究分析依折麦布对高脂血症并肝损患者的疗效与安全性。方法:选取22例肝损高胆固醇血症患者和24例混合型高脂血症患者,分组给予依折麦布治疗,观察两组肌毒性、肝毒性以及血脂变化。结果:在治疗后的第四周和第八周检查两组肝功能均未升高,治疗八周后LDL-C明显下降,混合型高脂血症组的TG与血TC下降尤为明显,差异存在统计学意义(P<0.05)。结论:依折麦布无需经P450酶细胞色素代谢,单纯使用依折麦布治疗高脂血症并肝损患者疗效显著,且有良好的耐受性和安全性。
Objective: To study the efficacy and safety of ezetimibe in patients with hyperlipidemia and liver damage. Methods: Twenty-two patients with hepatic hypercholesterolemia and 24 patients with mixed hyperlipidemia were enrolled and treated with ezetimibe in different groups. The changes of muscle toxicity, hepatotoxicity and blood lipid in the two groups were observed. Results: In the fourth week and the eighth week after treatment, the liver function of the two groups were not elevated, LDL-C decreased significantly after eight weeks of treatment, the TG and TC decreased significantly in mixed hyperlipidemia group, the difference There was statistical significance (P <0.05). CONCLUSION: Ezetimibe does not require cytochrome P450 enzyme metabolism. Ezetimibe alone can treat hyperlipidemia and liver damage in patients with significant efficacy, and has good tolerability and safety.